Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Masson-Lecomte

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 17, 2021
Achieving disease free distal ureteral margin at the time of radical cystectomy: Why and for whom? (an overview of literature)F Saint, A Masson-Lecomte
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]A Masson-Lecomte, P Maille, P Soyeux, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|July 6, 2023
[Preoperative chemotherapy for patients with upper tract urothelial carcinoma: Impact on renal function]P-E Gabriel, T Lambert, C Dumont, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 29, 2013
[Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis]A Masson-Lecomte, D Vordos, A de la Taille, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 1, 2013
[Oncological outcome of radical cystectomy for BCG failure compared to primary invasive disease]A Masson-Lecomte, D Vordos, R Yiou, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 11, 2019
[Is sarcopenia a morbi-mortality factor in the treatment of localized muscle-invasive bladder cancer?]G Fraisse, Y Renard, C Lebacle, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]D Charbit, F Vacherot, I El Sayed, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 16, 2020
[Active surveillance of prostate cancer: treatement-free survival according to restricted or expanded eligibility criteria]A Goujon, G Legrand, J Verine, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 18, 2021
Morbidity and long-term results of subcutaneous pyelovesical bypass in chronic ureteral obstructionA Nouaille, A Descazeaud, F Desgrandchamps, et al.
The French Journal of Urology|November 18, 2023
Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resectionQ Arnaud, P Sebe, A Colau, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 17, 2021
Achieving disease free distal ureteral margin at the time of radical cystectomy: Why and for whom? (an overview of literature)F Saint, A Masson-Lecomte
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]A Masson-Lecomte, P Maille, P Soyeux, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|July 6, 2023
[Preoperative chemotherapy for patients with upper tract urothelial carcinoma: Impact on renal function]P-E Gabriel, T Lambert, C Dumont, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 29, 2013
[Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis]A Masson-Lecomte, D Vordos, A de la Taille, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 1, 2013
[Oncological outcome of radical cystectomy for BCG failure compared to primary invasive disease]A Masson-Lecomte, D Vordos, R Yiou, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 11, 2019
[Is sarcopenia a morbi-mortality factor in the treatment of localized muscle-invasive bladder cancer?]G Fraisse, Y Renard, C Lebacle, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]D Charbit, F Vacherot, I El Sayed, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 16, 2020
[Active surveillance of prostate cancer: treatement-free survival according to restricted or expanded eligibility criteria]A Goujon, G Legrand, J Verine, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 18, 2021
Morbidity and long-term results of subcutaneous pyelovesical bypass in chronic ureteral obstructionA Nouaille, A Descazeaud, F Desgrandchamps, et al.
The French Journal of Urology|November 18, 2023
Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resectionQ Arnaud, P Sebe, A Colau, et al.
Pageof 4